Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit

Diabetes, Obesity and Metabolism

Volumn 20, Issue 1, 2018, Pages 185-194

  Heald, Adrian H ^a,b   Livingston, Mark ^c   Malipatil, Nagaraj ^a   Becher, Michal ^d   Craig, Joyce ^e   Stedman, Mike ^f   Fryer, Anthony A ^g,h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c MANOR HOSPITAL   (United Kingdom)

^d WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^e UNIVERSITY OF YORK   (United Kingdom)

^f Eastgate House   (United Kingdom)

^g KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^h UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

big data; diabetes; HbA1c; outcome; prescribing; primary care

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL AUDIT; CONTROLLED STUDY; DRUG COST; ETHNICITY; GENERAL PRACTICE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRESCRIPTION; SOCIAL STATUS; TREATMENT OUTCOME; UNITED KINGDOM; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG MONITORING; DRUG RESISTANCE; ECONOMICS; FEMALE; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MIDDLE AGED; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; TOTAL QUALITY MANAGEMENT;

AGED; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG MONITORING; DRUG RESISTANCE; FEMALE; GENERAL PRACTITIONERS; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MEDICAL AUDIT; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; QUALITY IMPROVEMENT; QUALITY OF HEALTH CARE; STATE MEDICINE; UNITED KINGDOM;

EID: 85029009678     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13067     Document Type: Article

References (25)

1. World Health Organization. Diabetes Factsheet. Geneva, Switzerland: World Health Organization; 2013.
2. Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med. 2010;27:938–948. https://doi.org/10.1111/j.1464-5491.2010.03040.x.
3. Massi-Benedetti M. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia. 2002;45:S1–S4. https://doi.org/10.1007/s00125-002-0860-3.
4. Bottomley JM, T2ARDIS Steering Committee. Managing care of type 2 diabetes. Learnings from T2ARDIS. Br J Diabetes Vasc Dis. 2001;1:68–72. https://doi.org/10.1177/14746514010010011201.
5. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany –results from the CODE-2 study. Exp Clin Endocrinol Diabetes. 2002;110:10–16. https://doi.org/10.1055/s-2002-19988.
6. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45:S13–S17. https://doi.org/10.1007/s00125-002-0859-9.
7. Liebl A, Khunti K, Orozco-Beltran D, Yale JF. Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review. Clin Med Insights Endocrinol Diabetes. 2015;8:13–19. https://doi.org/10.4137/CMED.S20906.
8. Type 2 diabetes in adults: management. NICE guideline [NG28]. https://www.nice.org.uk/guidance/NG28. Published December 2015. Updated July 2016. Accessed March 3, 2017.
9. Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. https://www.nice.org.uk/guidance/ng17. Published August 2015. Updated July 2016. Accessed March 3, 2017.
10. NHS Digital. Quality and Outcomes Framework (QOF) 2014–2015. http://content.digital.nhs.uk/searchcatalogue?productid=19196&q=title%3a%22Quality+and+Outcomes+Framework%22&sort=Relevance&size=10&page=2#top. October 2015. Accessed March 3, 2017.
11. Quality and Outcomes Framework; from NHS Digital downloaded Nov-15. http://content.digital.nhs.uk/searchcatalogue?productid=19196&q=title%3a%22Quality+and+Outcomes+Framework%22&sort=Relevance&size=10&page=2#top. Published 2015. Accessed March 3, 2017.
12. Diabetes Prevalence Model. London, England: Public Health England; 2016 http://www.yhpho.org.uk//resource/view.aspx?RID=241123. Accessed March 3, 2017.
13. Health England. DATA.GOV.UKNumber of patient registered at a GP practice (age, gender, ethnicity). Public https://data.gov.uk/dataset/numbers_of_patients_registered_at_a_gp_practice. 2016. Accessed March 3, 2017.
14. NHS Digital. UK National diabetes audit: 2013–2014 and 2014–2015: report 1, care processes and treatment targets. http://content.digital.nhs.uk/searchcatalogue?productid=20155&q=%22National+diabetes+audit%22&sort=Relevance&size=10&page=1#top. January 28, 2016. Accessed March 3, 2017.
15. NHS Digital. GP practice prescribing. http://content.digital.nhs.uk/searchcatalogue?q=title%3A%22presentation+level+data%22&area=&size=10&sort=Relevance. 2016. Accessed March 3, 2017.
16. Heald AH, Livingston M, Stedman M, Wyrko Z. Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson's disease. Int J Clin Pract. 2016;70:907–915. https://doi.org/10.1111/ijcp.12844.
17. WHO Collaborating Centre for Drug Statistics Methodology. Defined Daily Dose (DDD). ATC/DDD index. http://www.whocc.no/atc_ddd_index. August 2015. Accessed March 3, 2017.
18. Swinnen SG, Hoekstra JB, Devries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(suppl. 2):S253–S259.
19. Cambra K, Galbete A, Forga L, et al. Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. BMC Fam Pract. 2016;17:144.
20. Driskell OJ, Holland D, Waldron JL, et al. Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control. Diabetes Care. 2014;37:2731–2737. https://doi.org/10.2337/dc14-0297.
21. Marmot MG, Davey Smith G, Stansfeld S, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337:1387–1393. https://doi.org/10.1016/0140-6736(91)93068-K.
22. James GD, Baker P, Badrick E, Mathur R, Hull S, Robson J. Ethnic and social disparity in glycaemic control in type 2 diabetes; cohort study in general practice 2004–9. J R Soc Med. 2012;105:300–308. https://doi.org/10.1258/jrsm.2012.110289.
23. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45:S5–S12. https://doi.org/10.1007/s00125-002-0858-x.
24. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32:459–466. https://doi.org/10.1111/dme.12647.
25. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–862. https://doi.org/10.1111/j.1464-5491.2012.03698.x.